The Oncology Power Play: What's Behind BeOne Medicines' Deal with Revolution Medicines? The latest development in oncology research and development has left many industry observers puzzled.
BeOne Medicines AG, a NASDAQ listed biotech with a proven commercial track record, has partnered with Revolution Medicines to co develop and commercialize four clinical stage assets targeting RAS addicted cancers.
At first glance, this deal appears to be a win win for both parties – but closer examination reveals a more complex picture. The Commercial Engine vs. The High Burn Innovator BeOne's financial muscle is undeniable.